Literature DB >> 35979131

Unilateral adrenal tuberculosis whose computed tomography imaging characteristics mimic a malignant tumor: A case report.

Hui Liu1, Tian-Jiao Tang2, Zhen-Mei An3, Ye-Rong Yu4.   

Abstract

BACKGROUND: Adrenal tuberculosis usually presents with bilateral involvement. It has special characteristics in computed tomography (CT) images, such as small size, low attenuation in the center, and peripheral rim enhancement, which differ from those of primary tumors. CASE
SUMMARY: A 42-year-old female presented to the hospital with low back pain. She had been diagnosed with hypertension as well as pulmonary and cerebral tuberculosis but denied having any fever, fatigue, anorexia, night sweats, cough, or weight loss. Abdominal CT revealed an irregular 6.0 cm × 4.5 cm mass with uneven density in the right adrenal gland, while the left adrenal gland was normal. No abnormalities were observed in plasma total cortisol (8 am), adrenocorticotropic hormone, aldosterone/renin ratio, blood catecholamines, or urine catecholamines. A fine-needle aspiration biopsy of the right adrenal gland provided evidence of tuberculosis. After three years of anti-tuberculosis treatments, the large mass in the right adrenal gland was reduced to a slight enlargement.
CONCLUSION: This is a case of unilateral adrenal tuberculosis with CT imaging characteristics mimicking those of a malignant tumor. Extended anti-tuberculosis therapy is recommended in such cases. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Adrenal incidentaloma; Adrenal tuberculosis; Anti-tuberculosis therapy; Case report; Fine-needle aspiration biopsy

Year:  2022        PMID: 35979131      PMCID: PMC9258357          DOI: 10.12998/wjcc.v10.i17.5783

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.534


Core Tip: In this report, we report a female patient with unilateral adrenal tuberculosis whose CT image characteristics mimic those of a malignant tumor. After a long-term anti-tuberculosis regimen, the large mass in the right adrenal gland was reduced.

INTRODUCTION

Tuberculosis (TB) is known to present with varied clinical features, but involvement of the adrenal glands in TB is rare[1]. Isolated adrenal TB accounts for under 2% of adrenal incidentalomas[2], while 75%-100% of patients with adrenal TB have bilateral involvement[3-5]. As a result, unilateral adrenal TB is considered a rare clinical entity. The computed tomography (CT) imaging characteristics of adrenal TB are significantly different from those of primary tumors, such as small size, low attenuation in the center, and peripheral rim enhancement[3,6,7]. Herein, we report an unusual case of unilateral adrenal TB whose imaging characteristics were extremely atypical and suggested a high likelihood of a malignant tumor. Fine-needle aspiration biopsy (FNAB) was used to confirm TB, and prolonged anti-TB treatment was given to stabilize her condition.

CASE PRESENTATION

Chief complaints

A 42-year-old female was admitted to our department after presenting with a half-year history of osphyalgia.

History of present illness

A 42-year-old female had low back pain for a half year, which was exaggerated when taking a deep breath or lying flat and relieved when standing. She denied frequent micturition, painful urination, fever, hematuria, or pyuria.

History of past illness

The patient had a remote history of hypertension. She had been diagnosed with pulmonary and cerebral TB four months before presentation, and she had started a regimen of anti-TB drugs (isoniazid 0.3 g QD, rifampicin 0.45 g QD, ethambutol 0.75 g QD, and ofloxacin 0.5 g QD) upon diagnosis.

Personal and family history

Her personal and family history were insignificant.

Physical examination

Physical examination showed nothing special despite percussive pain in the right kidney area.

Laboratory examinations

Laboratory tests yielded the following results: plasma total cortisol (8 am), 594.6 nmol/L (reference, 147.3-609.3 nmol/L); adrenocorticotropic hormone, 48.30 ng/L (reference, 5.0-78 ng/L); and aldosterone/renin ratio, 16.92 ng/dL per ng/mL/h. No abnormalities were observed in the blood and urine catecholamines. Routine blood tests, routine urine tests, and biochemical tests were roughly in the normal range. CT-guided Fine needle aspiration biopsy (FNAB) of the right adrenal gland was performed, and pathological examination detected granulomas and necrosis (Figure 1A and B).
Figure 1

Microscopic examination of fine needle aspiration biopsy of the right adrenal gland showed Langerhans cells. A: Epithelioid cells; B: Necrosis; which were suggestive of tuberculosis infection.

Microscopic examination of fine needle aspiration biopsy of the right adrenal gland showed Langerhans cells. A: Epithelioid cells; B: Necrosis; which were suggestive of tuberculosis infection.

Imaging examinations

Four months prior to presentation, the patient had undergone an abdominal CT scan, which revealed a 1.5 cm isointense mass in the right adrenal gland (Figure 2A). On presentation to our department, she underwent another abdominal CT scan, which revealed a 6.0 cm × 4.5 cm irregular mass with uneven density in the right adrenal gland, while the left adrenal gland was normal (Figure 2B).
Figure 2

These were contrast-enhanced axial computed tomography images of the abdomen. A: Showed an isointense mass of 1.5 cm in the right adrenal gland; B: Showed an irregular mass of 6.0 cm × 4.5 cm with uneven density (20-30 HU in the central and 80-90 HU in the peripheral) in the right adrenal gland, while the left one was normal; C: Showed that the mass became smaller (2.7 cm × 2.4 cm) after anti-TB therapy for a total of 15 mo; D: Showed a slight enlargement of the right adrenal gland after about three years’ anti-TB therapy.

These were contrast-enhanced axial computed tomography images of the abdomen. A: Showed an isointense mass of 1.5 cm in the right adrenal gland; B: Showed an irregular mass of 6.0 cm × 4.5 cm with uneven density (20-30 HU in the central and 80-90 HU in the peripheral) in the right adrenal gland, while the left one was normal; C: Showed that the mass became smaller (2.7 cm × 2.4 cm) after anti-TB therapy for a total of 15 mo; D: Showed a slight enlargement of the right adrenal gland after about three years’ anti-TB therapy.

FINAL DIAGNOSIS

Unilateral adrenal tuberculosis.

TREATMENT

Treatment with 4 anti-TB drugs was continued.

OUTCOME AND FOLLOW-UP

The patient’s low back pain was relieved, and abdominal CT (Figure 2C) demonstrated a significant reduction of the mass in the right adrenal gland (2.7 cm × 2.4 cm) after 15 mo of anti-TB therapy. Three years later, abdominal CT (Figure 2D) showed a slight enlargement of the right adrenal gland.

DISCUSSION

Extrapulmonary TB constitutes about 15%-20% of all TB patients[8]. The most frequent sites of extrapulmonary TB include the lymph nodes (19%), pleural cavity (7%), gastrointestinal tract (4%), bone (6%), central nervous system (3%), and genitourinary system (1%)[9]. Of the 370 reports of extrapulmonary TB in a systematic review spanning 10 years[1], only one case was shown to involve the adrenal gland, which demonstrated adrenal TB as a rare clinical entity. Bilateral involvement usually occurs because of hematogenous and lymph spread from the site of the primary mycobacterial infection to both adrenal glands, which are equally susceptible[10]. In our case, adrenal TB (lesions of 1.5 cm to 5 cm) was aggravated while the anti-TB regimen was continued. It is necessary to distinguish adrenal masses from adrenal tumors. Adrenal incidentalomas, adenomas, metastases, adrenocortical carcinomas, myelolipomas, and pheochromocytomas accounted for 41%, 19%, 10%, 9%, and 8%, respectively. The etiologies of these partly depend on the size, such that larger tumors are more likely to be malignant. Adrenal carcinomas and metastases comprise 25% and 18% of lesions and are larger than 6 cm, while adenomas account for only 18%[11]. For tumors smaller than 4 cm, adrenal carcinomas comprise 2% and adenomas comprise 65%[11]. Untreated TB lesions were smaller than primary tumors (2.8 cm ± 1.3 cm vs 3.5 cm ± 2.4 cm)[6], while the diameters of benign, malignant pheochromocytoma and adrenocortical carcinoma were 5.7 cm ± 2.3 cm, 8.3 cm ± 4.1 cm[12] and 11 cm ± 4 cm[13], respectively. It is difficult to provide evidence with regard to TB based on size (6.0 cm × 4.5 cm) in this case. The CT value, attenuation measurement, and reduced central area (7 ± 4 HU) compared to the peripheral area (32 ± 14 HU) were observed between unenhanced and contrast-enhanced scans in adrenal TB[3]. This characteristic of central necrosis surrounded by fibrous and granulomatous inflammatory tissue is much less common in primary adrenal tumors[6], owing to sufficient blood supply in the central area. Pheochromocytoma always has a high enhancement of > 110 HU in the arterial phase[14], while adrenocortical carcinoma is less likely to show an enhancement of >100 HU. In the present case, evidence from images could not rule out a malignant tumor in the adrenal gland. In addition, calcification preferentially occurred in the later stages of adrenal TB than in adrenal tumors (59% vs 8%), which helped with a proper diagnosis[6]. In addition to the ineffectiveness of FNAB in distinguishing adrenal adenoma from adenocarcinoma[11], it is considered advantageous due to its ease, cost-effectiveness, reduced time consumption, low complication rates, and high accuracy[15-17]. It is often used for suspected nonfunctional and nonneoplastic adrenal gland lesions, but not employed for pheochromocytomas[11,17] due to the risk of hemodynamic instability. In the present case, blood pressure was well controlled and had no abnormalities in blood and urine catecholamines, indicating a lower possibility of pheochromocytoma. Therefore, FNAB was performed to obtain histological evidence, which subsequently provides clear evidence regarding targeted therapy. Patients with adrenal TB are usually treated with standard quadruple antitubercular treatment (such as isoniazid, rifampicin, pyrazinamide, and ethambutol)[18-20] for nearly 12 mo or longer. Adverse reactions to anti-TB drugs and their interactions with corticosteroids that are administered for replacement therapy remain challenging[21,22]. Firstly, rifampicin increases cortisol catabolism while isoniazid produces increased levels of cortisol via an opposite effect on the enzyme activity 6-Bhydroxylase; secondly, hepatitis, induced by isoniazid and worsened by rifampicin, leads to failure of 11-B-oxo-reductase, which converts cortisone to cortisol; and finally, tuberculous Addison’s disease might require increased amounts of hydrocortisone due to rifampicin administration[23]. Up to 70% of patients with active TB have subclinical adrenal insufficiency[24]. Anti-TB treatment might cause adrenal crisis[18], and patients should be closely monitored when starting this treatment. Most of the cases demonstrated a good response to anti-TB treatment. Early diagnosis and no delay in treatment initiation contributed to minimizing the high mortality rate[22,25]. Addison’s disease usually occurs when more than 90% of adrenal tissue has been destroyed[26]. Only a few patients with tuberculous Addison's disease showed recovery of adrenal function[27].

CONCLUSION

Unilateral adrenal tuberculous infection, although rare, should be considered in patients with unilateral adrenal mass but without Cushing syndrome, primary aldosteronism, or pheochromocytoma. FNAB assists in diagnosing TB, and early initiation and longer duration of anti-TB therapy are crucial to treating patients with unilateral adrenal tuberculous infection.
  25 in total

1.  Addison's disease due to adrenal tuberculosis: contrast-enhanced CT features and clinical duration correlation.

Authors:  Ying-Kun Guo; Zhi-Gang Yang; Yuan Li; En-Sen Ma; Yu-Ping Deng; Peng-Qiu Min; Long-Lin Yin; Jian Hu; Xiao-Chun Zhang; Tian-Wu Chen
Journal:  Eur J Radiol       Date:  2006-12-19       Impact factor: 3.528

2.  Differentiation between tuberculosis and primary tumors in the adrenal gland: evaluation with contrast-enhanced CT.

Authors:  Zhi-Gang Yang; Ying-Kun Guo; Yuan Li; Peng-Qiu Min; Jian-Qun Yu; En-Sen Ma
Journal:  Eur Radiol       Date:  2006-01-25       Impact factor: 5.315

3.  Rifampicin-induced adrenal crisis in a patient with tuberculosis: a therapeutic challenge.

Authors:  Nicholas Denny; Sarika Raghunath; Praveen Bhatia; Muntasir Abdelaziz
Journal:  BMJ Case Rep       Date:  2016-11-29

4.  MDCT of adrenal masses: Can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?

Authors:  Benjamin G Northcutt; Siva P Raman; Christopher Long; Alexander R Oshmyansky; Stanley S Siegelman; Elliot K Fishman; Pamela T Johnson
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

5.  Active tuberculosis unrecognised until necropsy.

Authors:  G P Edlin
Journal:  Lancet       Date:  1978-03-25       Impact factor: 79.321

6.  A critical examination of adrenal tuberculosis and a 28-year autopsy experience of active tuberculosis.

Authors:  K Y Lam; C Y Lo
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

Review 7.  Bilateral adrenal abnormalities: imaging review of different entities.

Authors:  Meshal Ali Alshahrani; Mnahi Bin Saeedan; Tariq Alkhunaizan; Ibtisam Musallam Aljohani; Fahad Mohammed Azzumeea
Journal:  Abdom Radiol (NY)       Date:  2019-01

8.  Study of adrenal function in patients with tuberculosis.

Authors:  Bipan Chander Sarin; Keerat Sibia; Sahiba Kukreja
Journal:  Indian J Tuberc       Date:  2017-10-07

9.  An autopsy case of unexpected death due to Addison's disease caused by adrenal tuberculosis.

Authors:  Nan Zhao; Yutong Gao; Chunsheng Ni; Danfang Zhang; Xiulan Zhao; Yanlei Li; Baocun Sun
Journal:  Eur J Med Res       Date:  2021-12-04       Impact factor: 2.175

10.  Adrenal insufficiency, be aware of drug interactions!

Authors:  Elke Thijs; Katrien Wierckx; Stefaan Vandecasteele; Annick Van den Bruel
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.